drugset / Trial / NCT01688947

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

NCT01688947

Phase 2 Completed 105 enrolled Purdue Pharma LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.

Timeline

Start
2012-09
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregabalin Small molecule Oral
Subject V116517 Unknown 30 mg Oral
Subject V116517 Unknown 50 mg Oral